Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
Alunbrig
|
| gptkbp:chemicalFormula |
C22H24ClN5O2S
|
| gptkbp:clinicalTrials |
combination therapy
Phase 2 monotherapy ALTA-1L trial ALTA_trial |
| gptkbp:contraindication |
anemia
headache hypertension vomiting rash thrombocytopenia visual disturbances neutropenia bradycardia severe hepatic impairment pulmonary toxicity hypersensitivity_to_brigatinib |
| gptkbp:date |
April 2017
|
| gptkbp:developedBy |
ARIAD Pharmaceuticals
|
| gptkbp:dosageForm |
90 mg once daily
|
| gptkbp:drugInterdiction |
food does not affect absorption
half-life 24 hours inhibits ROS1 phosphorylation peak plasma concentration 2-4 hours after administration inhibits_ALK_phosphorylation |
| gptkbp:formulation |
tablet
|
| gptkbp:hasPopulation |
ALK-positive NSCLC patients
|
| https://www.w3.org/2000/01/rdf-schema#label |
Brigatinib
|
| gptkbp:interactsWith |
CYP3A4 inhibitors
CYP3A4 inducers |
| gptkbp:isATypeOf |
1195760-54-0
|
| gptkbp:issuedBy |
oral tablet
|
| gptkbp:lastProduced |
2017
|
| gptkbp:mandates |
second-line treatment
first-line treatment |
| gptkbp:marketedAs |
Alunbrig
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:researchAreas |
oncology
targeted therapy precision medicine |
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
2019
|
| gptkbp:sideEffect |
fatigue
nausea diarrhea pneumonitis elevated liver enzymes |
| gptkbp:targets |
ALK gene rearrangements
ROS1 gene rearrangements |
| gptkbp:triggerType |
ALK_inhibitor
|
| gptkbp:usedFor |
non-small cell lung cancer
|
| gptkbp:waterManagement |
urine
feces |